Skip to content
Screener
Generate Biomedicines, Inc. logo

Generate Biomedicines, Inc.

GENB

Generate Biomedicines, Inc. is a asset management company in the financial services sector trading on XNAS, led by CEO Michael T. Nally, with a market cap of $1.8B.

Market cap
$1.82B+27.4%
Revenue$4.2M—
Net income-$87.7M—
Free cash flow-$57.0M—
EPS (diluted)-$0.68—
Quarterly · Q3 2026 · change vs. Q3 2025

Earnings

Next report

Feb 11, 2027 (in 3 months)
Revenue estimate$6.3M
EPS estimate-$0.67

Financials

Q3 2026

Income statement

See full
Revenue$4.2M—
Operating income-$91.5M—
Net income-$87.7M—
EPS (diluted)-$0.68—

Balance sheet

See full
Cash & equivalents$140.4M—
Total debt$75.3M—
Total equity$381.2M—
Total assets$515.9M—

Cash flow

See full
Operating cash flow-$54.9M—
CapEx$2.2M—
Free cash flow-$57.0M—

Valuation & ratios

Valuation

See full
Market cap$1.82B+27.4%
Enterprise value$1.76B—

Returns & leverage

See full
Debt / equity0.2×—
Current ratio5×—

Profile

Listed2026
CEOMichael T. Nally
FilingsSEC EDGAR

FAQ

What is Generate Biomedicines, Inc.'s market cap?
Generate Biomedicines, Inc. (GENB) has a market capitalization of $1.8B and trades on XNAS.
Where is Generate Biomedicines, Inc. headquartered?
Generate Biomedicines, Inc. is headquartered in United States of America. It has been publicly traded since 2026.